Marcel Verheij, MD, PhD, of Radboud University Medical Center, presents findings from the phase II CRITICS-II trial, which compared three preoperative regimens while omitting adjuvant treatment among patients with nonmetastatic resectable gastric cancer: chemotherapy, chemotherapy followed by chemoradiotherapy, and chemoradiotherapy (Abstract 283).
Elizabeth Smyth, MD, of the Oxford NIHR Biomedical Research Centre, Churchill Hospital, presents findings from an analysis of the MATTERHORN trial, a phase III study that examined fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab in patients with resectable gastric/gastroesophageal junction cancer. Dr. Smyth discusses rates of FLOT discontinuation along with event-free survival based on FLOT completion status in the trial (Abstract 343).
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, reviews the goals of the upcoming phase III ARTEMIDE-HCC01 trial, which will examine the efficacy and safety of rilvegostomig (a novel bispecific anti–PD-1/anti-TIGIT antibody) plus bevacizumab with or without tremelimumab as first-line treatment for unresectable hepatocellular carcinoma (Abstract TPS612).
Elena Elimova, MD, of Princess Margaret Cancer Centre, presents findings from the primary analysis of the phase III HERIZON-GEA-01 trial, which evaluated zanidatamab, a dual HER2-targeted bispecific antibody, plus chemotherapy with or without the PD-1 inhibitor tislelizumab vs trastuzumab plus chemotherapy as first line-regimens for HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (Abstract LBA285).
Stephen Lam Chan, MD, FRCP, MRCP, of the Hong Kong Cancer Institute, The Chinese University of Hong Kong, discusses findings from the phase III KEYNOTE-937 trial, which evaluated the efficacy and safety of pembrolizumab vs placebo as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who had undergone surgical resection or local ablation with curative intent (Abstract 477).
Daniela Molena, MD, of Memorial Sloan Kettering Cancer Center, discusses a comparison of the surgical journeys of patients with resectable gastric/gastroesophageal adenocarcinoma who either received fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab or FLOT plus placebo in the MATTERHORN study (Abstract 353).
